Concepedia

Publication | Closed Access

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.

110

Citations

15

References

2002

Year

Ronald D. Alvarez, Warner K. Huh, M.B. Khazaeli, Ruby F. Meredith, Edward E. Partridge, Larry C. Kilgore, William E. Grizzle, Sui Shen, J.Max Austin, Mack N. Barnes,
PubMed

Abstract

(90)Yttrium-CC49-based RIT in combination with IFN alpha2b and i.p. paclitaxel is feasible and well tolerated at a dose of < or =24.2 mCi/m(2).

References

YearCitations

Page 1